sentinel lymph node dissection (NSABP Foundation)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

NSABP Foundation sentinel lymph node dissection
Table 1

Sentinel Lymph Node Dissection, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymph+node+dissection/sentinel+lymph+node+dissection/pmc03907110-198-0-7
Average 90 stars, based on 1 article reviews

sentinel lymph node dissection - by Bioz Stars, 2026-10

90/100 stars

Images

1) Product Images from "Landmark Trials Affecting the Surgical Management of Invasive Breast Cancer"

Article Title: Landmark Trials Affecting the Surgical Management of Invasive Breast Cancer

Journal: The Surgical clinics of North America

doi: 10.1016/j.suc.2012.12.007

Figure Legend Snippet: Table 1

Techniques Used: Dissection

Dissection:

Article Title: CAGS and ACS Evidence Based Reviews in Surgery. 40
Article Snippet: Surgeons have been acutely aware of the long-term effects of ALND and for a number of years have commented on its declining impact on decision-making regarding systemic treatment for many patients 1 and troubling lack of survival benefit, as suggested in long-term follow-up of trials like the National Surgical Adjuvant Breast and Bowel Project’s (NSABP) B-04 protocol (comparison of radical mastectomy with alternative treatments). .. 2 The adoption of sentinel lymph node dissection (SLND) for patients with clinically negative axillae after studies such as ALMANAC (axillary lymphatic mapping against nodal axillary clearance) 3 and NSABP B-32 (comparison of sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients) 4 led to the elimination of completion dissections for patients with negative sentinel node biopsies. ..

Article Title: Landmark Trials Affecting the Surgical Management of Invasive Breast Cancer
Article Snippet: .. Sentinel Lymph Node Dissection for Axillary Staging NSABP B-32 To determine whether SLND renders the same survival benefit and regional control that ALND does but with fewer side effects in patients with clinically node-negative disease, NSABP investigators conducted the NSABP B-32 trial. ..

Article Title: Long-term morbidity after a negative sentinel node in breast cancer patients.
Article Snippet: .. Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection. ..

Article Title: Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer
Article Snippet: .. Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection . ..

Article Title: Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.
Article Snippet: .. 2018, 24 (5), 255−261. (35) Krag, D. N.; Julian, T. B.; Harlow, S. P.; Weaver, D. L.; Ashikaga, T.; Bryant, J.; Single, R. M.; Wolmark, N. NSABP-32: Phase III, Randomized Trial Comparing Axillary Resection with Sentinal Lymph Node Dissection: A Description of the Trial. ..

Comparison:

Control:

other:

Article Title: Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy.
Article Snippet: Introduction: The objective of our study was to assess recurrence after negative sentinel node biopsy (NSNB) and to determine risk factors related to local and distant recurrence in this group of patients.. Methods: This is a prospective observational study conducted from 2006 to 2011.. It included 607 patients with breast cancer in early stages and NSNB, with a 5-year follow up.

Article Title: Local and regional control in breast cancer: role of sentinel node biopsy.
Article Snippet: B reast cancer is the most common malignancy and the second most common cause of cancer deaths in American women.. The American Cancer Society estimates that 207,090 new cases of invasive breast cancer and 40,230 breast cancer deaths are expected in 2010 [1].. In patients with primary breast cancer, axillary lymph node status remains one of the most important prognostic indicators.

Article Title: The impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial: An institutional review.
Article Snippet: [3] Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial.

Review